Human parainfluenza viruses medical therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 7: | Line 7: | ||
::* 1. '''Adults''' | ::* 1. '''Adults''' | ||
:::* Preferred regimen: [[Ribavirin]] PO/IV 10 mg/kg q8h | :::* Preferred regimen: [[Ribavirin]] PO/IV 10 mg/kg q8h | ||
::::* Day 1: Start with 600 mg loading dose | ::::* Day 1: Start with 600 mg loading dose {{then}} 200 mg q8h | ||
::::* Day 2: 400 mg q8h | ::::* Day 2: 400 mg q8h | ||
::::* Day 3: Increase the dose to a maximum of 10 mg/kg q8h | ::::* Day 3: Increase the dose to a maximum of 10 mg/kg q8h |
Revision as of 21:01, 28 July 2015
Human parainfluenza viruses Microchapters |
Differentiating Human parainfluenza viruses from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Human parainfluenza viruses medical therapy On the Web |
American Roentgen Ray Society Images of Human parainfluenza viruses medical therapy |
Directions to Hospitals Treating Human parainfluenza viruses |
Risk calculators and risk factors for Human parainfluenza viruses medical therapy |
Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.
Antimicrobial regimen
- Parainfluenza virus[1]
- 1. Adults
- Preferred regimen: Ribavirin PO/IV 10 mg/kg q8h
- Day 1: Start with 600 mg loading dose THEN 200 mg q8h
- Day 2: 400 mg q8h
- Day 3: Increase the dose to a maximum of 10 mg/kg q8h
- 1.1 In case of adverse events
- Preferred regimen: Decrease dose or discontinue Ribavirin
- 1.2 Creatinine clearance
- 30–50 mL/min: Ribavirin PO/IV maximal 200 mg q8h
- 10–30 mL/ min: No recommendation can be given
References
- ↑ Hirsch HH, Martino R, Ward KN, Boeckh M, Einsele H, Ljungman P (2013). "Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis and treatment of human respiratory syncytial virus, parainfluenza virus, metapneumovirus, rhinovirus, and coronavirus". Clin Infect Dis. 56 (2): 258–66. doi:10.1093/cid/cis844. PMC 3526251. PMID 23024295.